AbbVie Inc.

🇺🇸New York Stock Exchange

Articles

46
Show Summary
Show Bulletpoints
Detailed View
Bullish +62

Adams Diversified Equity Fund Inc. Sells 58,300 Shares of AbbVie Inc ...

📉 Adams Diversified Equity Fund sold 58,300 AbbVie shares, reducing stake by 31.1%.

💰 AbbVie Q1 revenue hit $15 billion, beating analyst expectations of $14.72 billion.

📊 EPS reached $2.65, surpassing the consensus estimate of $2.59 by $0.06.

💵 Quarterly dividend declared at $1.73 with an annualized yield of 2.8%.

🔼 Analysts Piper Sandler and Canaccord Genuity raised price targets to $298 and $273.

📉 Adams Diversified Equity Fund Inc. sold 58,300 shares of AbbVie, reducing its position by 31.1% to hold 129,400 shares worth $28.1 million.

📈 Other institutional investors including Imprint Wealth LLC and Westend Capital Management LLC initiated or boosted their stakes in the fourth quarter.

💰 AbbVie reported Q1 revenue of $15 billion, a 12.4% increase year-over-year that exceeded analyst expectations of $14.72 billion.

📊 The company posted earnings per share of $2.65, beating the consensus estimate of $2.59 by $0.06.

💵 AbbVie declared a quarterly dividend of $1.73 with an ex-dividend date of July 15th and an annualized yield of 2.8%.

📈 Piper Sandler reissued an 'overweight' rating with a $298.00 price target on AbbVie shares.

🔼 Canaccord Genuity raised its price target from $265.00 to $273.00 and maintained a 'buy' rating.

📉 The stock carries a high payout ratio of 340.89% based on the declared dividend amount.

🏥 AbbVie's revenue growth was driven by its portfolio in immunology, oncology, neuroscience, virology, and women's health.

📊 MarketBeat data shows a consensus price target of $253.81 with an average rating of 'Moderate Buy'.

Bullish Signals
  • Revenue hit $15B, up 12.4% year-over-year.
  • EPS reached $2.65, beating estimates by $0.06.
  • Piper Sandler set price target at $298.
  • Canaccord raised target to $273 with buy rating.
  • Guggenheim maintains buy rating at $249 target.
  • Cantor Fitzgerald reiterated overweight rating on shares.
  • Dividend yield stands at 2.8% annually.
Risk Factors
  • High payout ratio of 340.89% exceeds earnings per share.
  • Negative return on equity of -576.45% for the quarter.
  • Institutional holder reduced position by 31.1% in Q1.
Bullish Signals
  • AbbVie reported revenue of $15 billion, representing a 12.4% year-over-year increase that surpassed analyst expectations of $14.72 billion.
  • The company posted earnings per share of $2.65, beating the consensus estimate of $2.59 by $0.06.
  • Piper Sandler reissued an 'overweight' rating and set a price target of $298.00 on AbbVie shares.
  • Canaccord Genuity raised its price target from $265.00 to $273.00 and reaffirmed a 'buy' rating.
  • Guggenheim reaffirmed a 'buy' rating with a price target of $249.00 on AbbVie stock.
  • Cantor Fitzgerald reiterated an 'overweight' rating on AbbVie shares in its latest research report.
  • AbbVie maintains a quarterly dividend of $1.73, providing an annualized yield of 2.8% to investors.
Risk Factors
  • AbbVie has a high payout ratio of 340.89%, indicating that the declared dividend exceeds current earnings per share.
  • The company reported a negative return on equity of -576.45% for the quarter.
  • Adams Diversified Equity Fund Inc., a significant institutional holder, reduced its position by 31.1% in the first quarter.
Bullish +75

حصلت شركة AbbVie (ABBV) على موافقة ... - albalad.news

📅 Canada approved Boey for facial lines in June 2026.

💉 Boey is the first short-acting Type E botulinum toxin.

🇪🇺 EU approved Maviret as sole treatment for hepatitis C.

📈 Canaccord raised AbbVie target price to $273 after Apogee deal.

⚖️ Analysts see AI stocks offering higher upside than AbbVie.

📅 في 23 يونيو 2026، وافقت وزارة الصحة الكندية على عقار Boey من AbbVie لتحسين خطوط الوجه لدى البالغين.

💉 يعتبر Boey أول نوع مصلي E معتمد من التوكسين العصبي البوتولينوم مع بداية سريعة ومدة قصيرة لهذا الغرض المحدد.

🇪🇺 وافقت المفوضية الأوروبية على عقار Maviret لعلاج عدوى فيروس التهاب الكبد الوبائي الحاد والمزمن لدى البالغين والأطفال فوق 3 سنوات.

💊 يُعد Maviret الآن العلاج الوحيد المعتمد في الاتحاد الأوروبي لكل من عدوى فيروس التهاب الكبد الوبائي الحاد والمزمن.

📈 رفعت Canaccord السعر المستهدف لأسهم AbbVie إلى 273 دولارًا من 265 دولارًا وحافظت على تصنيف الشراء.

🤝 جاء رفع السعر بعد استحواذ AbbVie المعلن على Apogee Therapeutics لإضافة أصول مناعية محتملة لمرض الزهايمر والربو.

🚀 يرى المحللون أن استحواذ Apogee قد يصبح محركًا رئيسيًا للنمو على مدى العقد المقبل.

🌍 تعمل AbbVie في جميع أنحاء العالم في البحث والتطوير وتصنيع وتسويق الأدوية والعلاجات.

📊 تُعد AbbVie واحدة من 12 سهمًا في مؤشر S&P 500 الأكثر ربحية للاستثمار فيها.

⚖️ يشير المقال إلى أن بعض أسهم الذكاء الاصطناعي قد توفر إمكانات صعودية أكبر وتحمل مخاطر هبوطية أقل من ABBV.

Bullish Signals
  • AbbVie received Canadian approval for Boey, first botulinum toxin type E.
  • EU approved Maviret as sole treatment for acute and chronic hepatitis C.
  • Canaccord raised AbbVie price target to $273 from $265.
  • AbbVie acquired Apogee Therapeutics for Alzheimer's and asthma assets.
  • AbbVie is one of 12 most profitable S&P 500 stocks.
Bullish Signals
  • حصلت AbbVie على موافقة كندية على عقار Boey، وهو أول نوع مصلي E معتمد من التوكسين العصبي البوتولينوم لتحسين خطوط الوجه لدى البالغين.
  • وافقت المفوضية الأوروبية على عقار Maviret لعلاج عدوى فيروس التهاب الكبد الوبائي الحاد والمزمن، مما يجعله العلاج الوحيد المعتمد في الاتحاد الأوروبي لهذه الحالات.
  • رفعت Canaccord السعر المستهدف لأسهم AbbVie إلى 273 دولارًا من 265 دولارًا وحافظت على تصنيف الشراء.
  • تم استحواذ AbbVie على Apogee Therapeutics لإضافة أصول مناعية ضخمة محتملة لمرض الزهايمر والربو، والتي يمكن أن تصبح محركًا رئيسيًا للنمو على مدى العقد المقبل.
  • تُعد AbbVie واحدة من 12 سهمًا في مؤشر S&P 500 الأكثر ربحية للاستثمار فيها.
Bullish +65

AbbVie Inc. $ABBV Position Increased by Apella Capital LLC

📈 Apella Capital increased AbbVie stake by 97.9% to 20,298 shares.

📊 AbbVie Q1 revenue hit $15B, beating estimates with $2.65 EPS.

💰 Quarterly dividend of $1.73 offers a 2.8% annualized yield.

🏆 DZ Bank upgraded to 'strong-buy' and BofA to 'buy'.

📉 Morgan Stanley raised target price to $278 with 'overweight' rating.

📈 Apella Capital LLC increased its AbbVie stake by 97.9% in Q1, adding 10,041 shares for a total holding of 20,298 shares valued at $4.23 million.

📊 AbbVie reported Q1 revenue of $15 billion, beating estimates of $14.72 billion, with EPS of $2.65 versus an expected $2.59.

📈 Revenue grew 12.4% year-over-year, and analysts maintain a consensus price target of $253.81 for the stock.

💰 The company declared a quarterly dividend of $1.73 per share with an annualized yield of 2.8% payable on August 14th.

🏆 DZ Bank upgraded AbbVie to 'strong-buy' and Bank of America upgraded it to 'buy' with a $234 price objective.

📉 Morgan Stanley raised its target price from $270.00 to $278.00 while reaffirming an 'overweight' rating.

🏛️ Institutional ownership stands at 70.23%, with multiple wealth management firms increasing their positions in Q1.

Bullish Signals
  • AbbVie beat earnings with $2.65 EPS vs $2.59 consensus.
  • Revenue hit $15 billion, beating the $14.72B estimate.
  • Revenue grew 12.4% year-over-year.
  • DZ Bank upgraded stock to 'strong-buy'.
  • Bank of America set $234 price target.
Bullish Signals
  • AbbVie beat quarterly earnings estimates with $2.65 EPS compared to the consensus of $2.59.
  • Revenue reached $15 billion, exceeding analyst expectations of $14.72 billion.
  • The company achieved a 12.4% year-over-year revenue increase.
  • DZ Bank upgraded the stock rating from 'hold' to 'strong-buy'.
  • Bank of America upgraded the rating to 'buy' and set a $234 price objective.
  • Morgan Stanley increased its target price to $278.00.
  • Apella Capital LLC significantly boosted its position by 97.9% in Q1.
  • Multiple institutional investors including Thoma Capital and Consilium Wealth Advisory increased their stakes.
Bullish +55

ABBV: Game-Changing Data on Venetoclax Unveiled!

📈 Venetoclax offers ~8 years off-treatment in first-line CLL per nine-year trial data.

💰 Board approved a 5.8% dividend hike to $1.64/share starting February 2025.

💵 AbbVie generated $18.8B operating cash flow in 2024 with $7B+ free cash flow.

📉 Total long-term debt was ~$67B at year-end 2024 after paying down $9.6B.

🏆 Moody's upgraded credit rating to A2 Stable citing strong post-Humira performance.

📈 AbbVie unveiled nine-year follow-up data from the CLL14 trial showing venetoclax provides a median of ~8 years off treatment in first-line chronic lymphocytic leukemia.

💰 The board approved a ~5.8% quarterly dividend hike to $1.64 per share starting February 2025, maintaining a streak of annual increases since the 2013 spin-off.

💵 AbbVie generated $18.8 billion in operating cash flow in 2024, funding $11.0 billion in dividends and leaving over $7 billion in free cash flow.

📉 Total long-term debt stood at about $67 billion as of year-end 2024, with the company paying down a net $9.6 billion in 2024 to reduce leverage.

🏆 Moody's upgraded AbbVie's credit rating to A2 Stable in early 2026, citing improving post-Humira performance and strong free cash flow generation.

📊 Shares rallied approximately 25% over the past year as of early 2026, driven by optimism in new immunology and oncology products.

⚠️ Humira U.S. patent expired in January 2023, causing sales to plunge 41% in 2024 as the company transitions to newer therapies.

🔬 Skyrizi revenue jumped ~76% in 2022 with continued double-digit growth through 2024, helping offset declines in legacy immunology drugs.

⚖️ AbbVie carries over $70 billion in goodwill and intangible assets, taking a $3.5 billion impairment charge on certain assets in 2024.

📉 U.S. Medicare negotiations under the Inflation Reduction Act have targeted AbbVie's Imbruvica for future price controls.

Bullish Signals
  • CLL14 trial confirms ~8 years off treatment for venetoclax.
  • Dividend increased ~5.8% to $1.64/share starting Feb 2025.
  • Generated $18.8B operating cash flow in 2024.
  • Moody's upgraded credit rating to A2 Stable.
  • Paid down net $9.6B debt in 2024.
  • Shares returned ~25% over past year.
  • Skyrizi revenue jumped ~76% in 2022.
Risk Factors
  • GAAP P/E exceeds 100 due to heavy non-cash amortization charges.
  • $67 billion debt load limits flexibility for future acquisitions or R&D.
  • $3.5 billion impairment charge on intangible assets in 2024.
  • Humira, Skyrizi, and Rinvoq account for ~47% of total revenue.
Bullish Signals
  • Landmark nine-year data from the CLL14 trial confirms venetoclax offers a median of ~8 years off treatment, affirming its safety and efficacy in first-line chronic lymphocytic leukemia.
  • AbbVie increased its quarterly dividend by ~5.8% to $1.64 per share starting February 2025, extending a multi-year streak of consistent dividend growth.
  • The company generated $18.8 billion in operating cash flow in 2024, easily funding dividends and leaving over $7 billion in free cash flow for debt reduction or investments.
  • Moody's upgraded AbbVie's credit rating to A2 Stable with a stable outlook, reflecting improving post-Humira performance and robust annual free cash flow exceeding $10 billion after dividends.
  • AbbVie paid down a net $9.6 billion of debt in 2024 while maintaining investment-grade ratings (S&P affirmed A–), demonstrating active balance sheet management.
  • Shares returned about 25% over the past year as of early 2026, reflecting strong market confidence in the company's new immunology and oncology product pipeline.
  • Skyrizi revenue grew rapidly with a ~76% jump in 2022 and sustained double-digit growth through 2024, signaling successful replacement of legacy drug sales.
Risk Factors
  • AbbVie's GAAP P/E ratio exceeds 100 due to heavy non-cash amortization charges, making the stock appear richly valued on trailing earnings despite a more reasonable forward multiple.
  • The company carries a significant debt load of approximately $67 billion as of year-end 2024, which limits flexibility for future acquisitions or major R&D spending spikes.
  • AbbVie took a $3.5 billion impairment charge on certain intangible assets in 2024, reflecting disappointments in parts of its acquired portfolio and signaling potential underperformance.
  • Humira, Skyrizi, and Rinvoq together accounted for ~47% of total revenue in 2024, creating high product concentration risk if new drugs fail to fully replace Humira's peak sales.
Bullish +65

Should You Buy Or Sell AbbVie Stock At $230? - Trefis

📈 Stock rose 6.25% on $11B Apogee acquisition.

💰 Revenue grew 12.4% to $15.0B despite Humira drop.

🔬 Skyrizi sales surged 29.2% to $4.5 billion.

⚠️ Oncology revenues slipped 3% amid macro headwinds.

📉 Net margins at 5.8% due to R&D write-offs.

📈 AbbVie stock rose 6.25% following the announcement of a nearly $11 billion all-cash acquisition of Apogee Therapeutics to strengthen its immunology pipeline.

💰 Total company revenue grew 12.4% year-over-year to $15.0 billion in the most recent quarter despite a 40.3% decline in legacy Humira sales.

🔬 Skyrizi sales surged 29.2% to $4.5 billion while Rinvoq global sales climbed 20.2% to $2.1 billion, successfully replacing blockbuster revenue.

💵 The company generated approximately $21.2 billion in operating cash flow over the last year, converting 33.8% of its total revenue into cash.

📊 AbbVie trades at a forward price-to-earnings ratio of 16x, which is higher than its four-year average of 13x and significantly above the market's 3.2x P/S ratio.

⚖️ Operating margins remain elite at 33.2%, substantially outperforming the broader market average of 18.4%.

🏦 Debt levels are manageable at 19.0% of market capitalization, sitting below the broader market average of 21.3%.

⚠️ Oncology segment revenues slipped by 3% and Juvederm aesthetic filler sales fell 2.9% amid macroeconomic headwinds.

📉 Net margins sit at 5.8% versus the S&P 500's 13.0%, primarily due to $12.7 billion in pre-tax acquired IPR&D and milestone write-offs.

🎯 The Apogee acquisition carries binary clinical execution risk, specifically regarding the safety profile of Zumilokibart in Phase 3 trials.

📉 High Beta Risk: The stock fell 23% during the 2022 inflation shock and 34% during the 2020 pandemic crash, matching broader market declines.

📈 Options market implied volatility stands at 27, placing it in the 74th percentile and indicating traders expect larger-than-average price swings.

Bullish Signals
  • Total revenue grew 12.4% despite a 40.3% Humira sales drop.
  • Skyrizi sales surged 29.2% to $4.5 billion.
  • Rinvoq global sales climbed 20.2% to $2.1 billion.
  • Neuroscience revenues jumped 24.3% to nearly $2.9 billion.
  • Elite operating margin of 33.2% outperforms market average of 18.4%.
  • Converts 33.8% of revenue into operating cash flow.
  • Absorbed $11 billion Apogee acquisition without debt or dilution.
  • Stock rallied 6.25% after Apogee deal announcement.
Risk Factors
  • Forward P/E of 16x exceeds four-year average of 13x.
  • On oncology revenues slipped 3% amid key therapeutic weakness.
  • Juvederm sales fell 2.9% due to macroeconomic headwinds.
  • Net margins compressed to 5.8% versus S&P 500's 13.0%.
  • $12.7 billion pre-tax write-offs from ImmunoGen and Cerevel deals.
Bullish Signals
  • AbbVie successfully navigated its historic patent cliff, replacing Humira revenue with aggressive growth from Skyrizi and Rinvoq.
  • The company demonstrated operational detachment from past anchors by growing total revenue 12.4% despite a 40.3% drop in Humira sales.
  • Skyrizi sales surged 29.2% to $4.5 billion, establishing itself as a dominant new franchise in the immunology space.
  • Rinvoq global sales climbed 20.2% to $2.1 billion, further diversifying the company's high-growth portfolio.
  • Neuroscience revenues jumped 24.3% to nearly $2.9 billion, showing strength in a second major growth segment.
  • The company possesses an elite operating margin of 33.2%, significantly outperforming the broader market average of 18.4%.
  • AbbVie is a powerful cash-generation machine, converting 33.8% of revenue into operating cash flow to fund acquisitions and R&D.
  • The balance sheet is pristine with ample liquidity to absorb the $11 billion Apogee acquisition without diluting shareholders or taking on burdensome debt.
  • The stock rallied 6.25% immediately after the Apogee deal announcement, signaling strong investor confidence in the strategic value of the acquisition.
Risk Factors
  • AbbVie trades at a significant premium with a forward P/E of 16x versus its four-year average of 13x, leaving little room for error.
  • The oncology segment saw revenues slip by 3%, indicating weakness in a key therapeutic area.
  • Sales of Juvederm aesthetic fillers fell 2.9% amid lingering macroeconomic headwinds, adding to revenue pressure.
  • Net margins are compressed at 5.8% compared to the S&P 500's 13.0% due to aggressive M&A activity and associated write-offs.
  • The company recorded $12.7 billion in pre-tax acquired IPR&D and milestone write-offs over the trailing twelve months from deals like ImmunoGen and Cerevel.
  • Elevated Volatility: Options market implied volatility is at 27 (74th percentile), suggesting traders brace for larger-than-average price swings.
  • Clinical Execution Risk: The $11 billion Apogee deal carries binary risk; if Zumilokibart encounters safety issues or fails Phase 3 trials, the high valuation could face a sharp reset.
Bullish +65

Claris Financial LLC Makes New $1.79 Million Investment in AbbVie Inc ...

📈 Claris Financial bought 7,840 shares worth $1.79 million in Q4.

📊 Other investors opened new positions ranging from $26k to $31k.

💰 Revenue hit $15 billion, a 12.4% increase beating estimates.

📉 EPS reached $2.65, topping the consensus by $0.06.

💵 Quarterly dividend of $1.73 per share set for August 14th.

📈 Claris Financial LLC purchased a new stake of 7,840 shares in AbbVie valued at approximately $1.79 million during the fourth quarter.

📊 Several other institutional investors including Chelsea Counsel Co., Litman Gregory Wealth Management LLC, and Westend Capital Management LLC established new positions ranging from $26,000 to $31,000.

💰 AbbVie reported quarterly revenue of $15 billion, representing a 12.4% year-over-year increase that beat analyst estimates.

📉 The company posted earnings per share of $2.65, topping the consensus estimate of $2.59 by $0.06.

💵 AbbVie announced a quarterly dividend of $1.73 per share to be paid on August 14th with an ex-dividend date of July 15th.

📈 The stock currently trades at a PE ratio of 106.71 and has a market capitalization of $382.74 billion.

🔬 AbbVie's product portfolio covers major therapeutic categories including immunology, oncology, neuroscience, virology, and women's health.

Bullish Signals
  • Revenue hit $15B, up 12.4% year-over-year.
  • EPS of $2.65 beat the $2.59 consensus.
  • Institutional ownership stands at 70.23%.
  • Dividend yield reaches 3.2%.
  • Revenue exceeded expectations of $14.72B.
Risk Factors
  • Stock trades below 200-day moving average of $218.78.
  • Payout ratio of 340.89% indicates dividend paid from capital.
Bullish Signals
  • AbbVie reported revenue of $15 billion for the quarter, which is a 12.4% increase compared to the previous year.
  • The company beat analyst earnings estimates with EPS of $2.65 versus a consensus of $2.59.
  • Institutional interest remains strong with hedge funds and other institutional investors owning 70.23% of the company's stock.
  • AbbVie has established a consistent dividend history, offering a yield of 3.2% on its recent quarterly payout.
  • The company successfully expanded its revenue base beyond analyst expectations of $14.72 billion.
Risk Factors
  • AbbVie's stock is trading below its 200-day moving average of $218.78, indicating potential short-term weakness relative to longer-term trends.
  • The company has a high payout ratio of 340.89%, which suggests the dividend is being paid from capital rather than current earnings.
Bullish +65

AbbVie Inc. (ABBV) Presents Data on Fixed-Duration Venetoclax-Based Combination

📊 CLL14 trial: Venetoclax + obinutuzumab showed 6.4-year median progression-free survival vs 3.2 years.

🇪🇺 EU approved Venclyxto expansion for acalabrutinib/ibrutinib combos in previously untreated CLL on May 29, 2026.

💊 FDA approved DECNUPAZ for BPDCN with 69.7% composite complete response rate based on CADENZA trial data.

📈 Fixed-duration regimens offer targeted oral options and potential treatment breaks in first-line settings.

🔬 AbbVie expands oncology portfolio with approvals in CLL and ultra-rare hematologic malignancies.

📊 AbbVie presented Phase 3 CLL14 trial data showing venetoclax plus obinutuzumab achieved a median progression-free survival of 6.4 years versus 3.2 years for the comparator in previously untreated chronic lymphocytic leukemia.

🇪🇺 The European Commission authorized an expanded label for Venclyxto on May 29, 2026, including use with acalabrutinib or ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia in the EU and EEA.

💊 The FDA approved DECNUPAZ (pivekimab sunirine-pvzy) on May 27, 2026, for treating adult patients with BPDCN based on Phase 1/2 CADENZA trial data showing a 69.7% composite complete response rate in newly diagnosed patients.

📈 The fixed-duration regimens support current standards of care and provide additional targeted oral medication options in the first-line setting, including potential for time off treatment.

🔬 AbbVie's oncology portfolio expands with approvals in chronic lymphocytic leukemia and ultra-rare hematologic malignancies, reinforcing its therapeutic focus.

Bullish Signals
  • FDA approved DECNUPAZ for adult BPDCN with limited options.
  • EU expanded Venclyxto label for CLL combo therapy.
  • CLL14 trial showed 6.4 vs 3.2 years progression-free survival.
  • Fixed-duration regimens offer treatment breaks and better quality of life.
Bullish Signals
  • AbbVie received FDA approval for DECNUPAZ (pivekimab sunirine-pvzy) for treating adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options.
  • The European Commission authorized an expanded label for Venclyxto to include use in combination with acalabrutinib or ibrutinib for previously untreated chronic lymphocytic leukemia, extending availability across the EU and EEA.
  • Phase 3 CLL14 trial data demonstrated a significant improvement in progression-free survival (6.4 years vs. 3.2 years) for venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab after a median follow-up of 9.2 years.
  • The new fixed-duration combination regimens support current standards of care and offer patients the potential for time off treatment, enhancing patient convenience and quality of life.
Bullish +72

AbbVie Stock Will Hit $300 on This Date

📈 Q1 2026 revenue accelerated +12.4% YoY exceeding expectations.

💊 Immunology segment hit $7.29B with Skyrizi up 30.9%.

📉 Net income dropped 45.96% due to a $744M R&D charge.

🎯 Stock trades at 17x forward P/E vs $253.55 consensus target.

🚀 Skyrizi crossed $5.01B quarterly revenue growing over 30%.

📈 CEO Robert A. Michael confirmed Q1 2026 results exceeded expectations with revenue accelerating to +12.4% YoY.

💊 Immunology segment generated $7.29 billion, with Skyrizi up 30.9% and Rinvoq up 23.3%.

📉 Net income fell 45.96% YoY primarily due to a $744 million acquired-in-process R&D charge.

💸 Legacy franchises Humira and Imbruvica declined by 38.6% and 24.7% respectively, creating revenue headwinds.

🎯 Wall Street consensus target is $253.55, while the author's model projects a base case of $245.35.

🚀 Skyrizi crossed $5.01 billion in quarterly revenue and continues growing at over 30%.

🧠 Neuroscience franchise Qulipta showed strong momentum with a 53.6% increase in performance.

💰 Stock trades at a forward P/E of 17x, appearing cheap given operating margins above 32%.

📅 The author's 5-year bull case models the stock reaching $301 by June 2030.

⚠️ Primary risk identified is faster-than-expected erosion across the legacy oncology franchise.

Bullish Signals
  • Q1 2026 revenue accelerated +12.4% year-over-year.
  • Immunology revenue hit $7.29 billion driven by growth.
  • Skyrizi crossed $5.01 billion with >30% growth rate.
  • Neuroscience franchise Qulipta increased performance 53.6%.
  • Stock trades at forward P/E of 17x vs 32% margins.
  • Management raised full-year guidance to $14.08-$14.28.
  • Stock returned 457.85% over 10 years historically.
  • Analysts rate stock bullish with 24 total ratings.
Risk Factors
  • Net income fell 45.96% due to $744 million R&D charge.
  • Revenue dropped 38.6% as Humira franchise structurally declined.
  • Imbruvica revenue declined 24.7%, pressuring overall top-line growth.
  • Market may treat one-time charges as recurring, depressing multiples.
  • Erosion could derail path to $300 legacy oncology target.
Bullish Signals
  • Q1 2026 results exceeded expectations with revenue accelerating to +12.4% year-over-year despite market noise.
  • Immunology revenue hit $7.29 billion, driven by Skyrizi growth of 30.9% and Rinvoq growth of 23.3%.
  • Skyrizi crossed the $5.01 billion revenue mark last quarter while maintaining a growth rate above 30%.
  • Neuroscience franchise Qulipta demonstrated exceptional momentum with a 53.6% increase in performance.
  • The stock trades at a forward P/E of 17x against operating margins exceeding 32%, indicating potential undervaluation.
  • Management raised full-year guidance to $14.08-$14.28, signaling confidence in future earnings power.
  • Historical performance shows the stock returned 457.85% over 10 years and 131.55% over five years.
  • Analyst consensus remains overwhelmingly bullish with 8 Strong Buy and 16 Buy ratings out of 24 total.
Risk Factors
  • Net income fell 45.96% year-over-year due to a $744 million acquired-in-process R&D charge that clipped EPS by $0.41.
  • Structural decline in the Humira franchise caused revenue to fall 38.6% to $688 million.
  • Imbruvica revenue declined by 24.7%, adding pressure to overall top-line growth.
  • The market treats one-time R&D charges as recurring damage, potentially depressing valuation multiples.
  • Faster-than-expected erosion across the legacy oncology franchise could derail the path to $300.
  • Mega-cap dampening effects may cap the adjustment factor in valuation models despite sector momentum.
Slightly Bullish +25

AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy

📈 Skyrizi and Rinvoq surpass Humira peak sales.

💰 Stock trades at 14.8x forward P/E below peers.

🚀 Management guides double-digit immunology growth through 2026.

⚠️ High leverage with $52.3 billion in net debt.

📉 Analysts rate stock 'hold' advising accumulation on weakness.

📈 Skyrizi and Rinvoq have surpassed Humira's peak sales, successfully replacing lost revenue.

💰 The stock trades at a forward P/E of 14.8x, below the pharmaceutical peer average.

🚀 Management guides for double-digit immunology sales growth through 2026.

⚠️ High leverage is evident with approximately $52.3 billion in net debt.

🛡️ The company offers a defensive investment case with strong dividend yield.

📉 Analyst rates the stock as a 'hold' advising accumulation only on weakness.

🔬 Pipeline execution risk remains a key factor tempering investor enthusiasm.

Bullish Signals
  • Skyrizi and Rinvoq now exceed Humira's peak sales.
  • Forward P/E of 14.8x is below peer average.
  • Guiding for double-digit immunology sales growth through 2026.
  • Strong dividend yield offers a defensive investment profile.
Risk Factors
  • $52.3B net debt constrains financial flexibility.
  • Analyst advises against buying; fair valuation.
Bullish Signals
  • AbbVie has successfully replaced Humira's lost revenue with Skyrizi and Rinvoq, which now exceed the former blockbuster's peak sales.
  • The company trades at a forward P/E of 14.8x, offering a valuation below the pharmaceutical peer average.
  • Management is guiding for double-digit immunology sales growth through 2026, indicating strong future performance.
  • AbbVie provides a defensive investment profile with a strong dividend yield suitable for uncertain macro environments.
Risk Factors
  • The company carries high leverage with approximately $52.3 billion in net debt, which could constrain financial flexibility.
  • The analyst advises against buying at current levels, suggesting accumulation only on market weakness due to fair rather than cheap valuation.
Bullish +65

Coca-Cola, UnitedHealth, Sabra Health Care: CNBC’s Final Trades - AbbVie (NYSE:ABBV), Coca-Cola (NYSE:KO) - Benzinga

📈 Bill Baruch selected AbbVie as his final CNBC trade.

🏥 AbbVie got EU approval for VENCLYXTO in chronic lymphocytic leukemia.

📈 Shares rose 1% to close at $227.23 after news.

💰 New label expands drug utility and potential revenue streams.

📈 Bill Baruch, founder and CIO of Blue Line Capital and Blue Creek Capital Management, selected AbbVie Inc. (NYSE: ABBV) as his final trade on CNBC.

🏥 On May 29, AbbVie received European Commission authorization to expand the label for VENCLYXTO® (venetoclax) to include new combinations for previously untreated chronic lymphocytic leukemia.

📈 AbbVie shares rose 1% to close at $227.23 during the trading session following the news and analyst coverage.

💰 The regulatory approval expands the drug's utility in treating a specific form of blood cancer, potentially opening new revenue streams for the oncology portfolio.

📊 CNBC's 'Final Trades' segment also highlighted positive momentum for Coca-Cola, UnitedHealth Group, and Sabra Health Care, though AbbVie was the primary focus of this specific ticker analysis.

Bullish Signals
  • Bill Baruch gives AbbVie a strong buy recommendation.
  • European Commission authorizes expanded VENCLYXTO® label for CLL.
  • AbbVie shares rise 1% to settle at $227.23.
  • Regulatory expansion validates AbbVie's oncology R&D efforts.
Bullish Signals
  • AbbVie received a strong buy recommendation from Bill Baruch, a prominent figure in the investment community managing Blue Line Capital and Blue Creek Capital Management.
  • The European Commission has officially authorized an expanded label for VENCLYXTO® (venetoclax), allowing it to be used with additional combinations for previously untreated chronic lymphocytic leukemia.
  • AbbVie shares demonstrated positive momentum, rising 1% to settle at $227.23 during the session.
  • The regulatory expansion of venetoclax represents a significant milestone in the company's oncology pipeline, validating its R&D efforts in blood cancer treatments.
Bullish +55

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

📊 AbbVie presents six oral blood cancer data at EHA 2026.

💉 Low-risk follicular lymphoma ORR reaches 96.5% with epcoritamab combo.

📈 DLBCL monotherapy PFS improves to 30% vs 13% for chemo.

⚠️ Epcoritamab shows higher grade 3-4 infections and COVID-19 rates.

🧬 CLL14 confirms venetoclax-obinutuzumab efficacy in untreated chronic lymphocytic leukemia.

📊 AbbVie presents new clinical data at EHA 2026 covering six oral presentations across multiple blood cancer indications.

💉 EPCORE FL-1 trial subgroup analysis shows epcoritamab + lenalidomide/rituximab achieves 96.5% ORR in low-risk follicular lymphoma vs 84.8% for comparator.

📈 EPCORE DLBCL-1 results show epcoritamab monotherapy improves PFS vs chemoimmunotherapy (HR 0.74) with 30% vs 13% 24-month PFS.

🧬 CLL14 trial final results confirm venetoclax-obinutuzumab efficacy in previously untreated chronic lymphocytic leukemia patients.

🔬 REVIVE study presents real-world management practices for venetoclax-based therapy in newly diagnosed AML patients unfit for intensive chemotherapy.

🧪 Etentamig (ABBV-383) data presented for relapsed/refractory multiple myeloma with prior BCMA exposure and amyloidosis.

🩺 Pivekimab sunirine-pvzy efficacy data shown in blastic plasmacytoid dendritic cell neoplasm with skin involvement.

🤝 EPKINLY and VENCLEXTA are approved therapies being investigated for additional uses; etentamig and pivekimab remain investigational.

⚠️ Epcoritamab arm reported higher rates of grade 3-4 infections (30% vs 12%) and COVID-19 (36% vs 11%) in DLBCL trial.

📅 Full abstracts available via PR Newswire link; presentations held June 8, 2026 at EHA Congress in Stockholm.

Bullish Signals
  • 96.5% vs 84.8% ORR in low-risk EPCORE FL-1 subgroup.
  • PFS HR 0.74; p=0.0059 for epcoritamab monotherapy in EPCORE DLBCL-1.
  • Venetoclax-obinutuzumab effective in previously untreated CLL patients.
  • Sustained remissions beyond 4 years confirmed in EPCORE NHL-1.
  • Improved QoL with epcoritamab for high symptom burden patients.
Risk Factors
  • Higher grade 3-4 infections (30% vs 12%) and COVID-19 (36% vs 11%).
  • Grade 5 adverse events in 17% of epcoritamab patients.
  • No significant overall survival improvement (HR 0.96; p=0.28).
  • Etentamig and pivekimab sunirine-pvzy remain investigational with no EU approval.
  • Lower ORR in high-risk FLIPI patients (72.6%) vs low-risk (93.0%).
Bullish Signals
  • EPCORE FL-1 subgroup analysis shows numerically higher overall response rates with epcoritamab + lenalidomide/rituximab across risk groups (96.5% vs 84.8% in low-risk).
  • EPCORE DLBCL-1 demonstrates statistically significant PFS improvement for epcoritamab monotherapy vs chemoimmunotherapy (HR 0.74; p=0.0059).
  • CLL14 trial final results support venetoclax-obinutuzumab as effective regimen in previously untreated CLL patients.
  • Real-world REVIVE study provides practical insights into venetoclax-based therapy management for AML in chemotherapy-unfit patients.
  • Etentamig shows promise in relapsed/refractory multiple myeloma with prior BCMA exposure, including triple-class resistance.
  • Pivekimab sunirine-pvzy demonstrates activity in rare BPDCN with skin involvement, supporting first-line use potential.
  • Long-term follow-up from EPCORE NHL-1 trial confirms sustained remissions beyond 4 years with epcoritamab monotherapy.
  • EPCORE FL-1 data supports improved or preserved health-related quality of life in patients with high symptom burden.
Risk Factors
  • In EPCORE DLBCL-1, epcoritamab arm reported higher rates of grade 3-4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%).
  • Grade 5 treatment-emergent adverse events occurred in 17% of epcoritamab patients vs 6% in comparator, largely due to severe COVID-19 cases.
  • EPCORE DLBCL-1 did not demonstrate statistically significant improvement in overall survival (HR 0.96; p=0.28).
  • Etentamig and pivekimab sunirine-pvzy remain investigational with no EU approval as of June 2026.
  • EPCORE FL-1 subgroup analysis noted lower ORR in high-risk FLIPI patients (93.0% vs 72.6%) compared to low-risk counterparts.
Bullish +65

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

📅 AbbVie presents new data at EHA 2026 Congress in Stockholm on June 8, 2026.

💊 Approved therapies include EPKINLY, VENCLEXTA, and DECNUPAZ for six blood cancer types.

📈 EPCORE FL-1 shows higher response rates; EPCORE DLBCL-1 shows improved survival vs chemoimmunotherapy.

⚠️ Safety warnings cover infections, CRS, neurologic issues, and tumor lysis syndrome risks.

🧪 Studies evaluate venetoclax, etentamig, and pivekimab sunirine-pvzy across various cancer indications.

📅 AbbVie is presenting new data at the European Hematology Association (EHA) 2026 Congress in Stockholm on June 8, 2026.

🔬 Six oral presentations and multiple posters highlight advancements across six blood cancer types: MM, FL, CLL, DLBCL, AML, and amyloidosis.

💊 Approved therapies featured include EPKINLY (epcoritamab-bysp), VENCLEXTA (venetoclax), and DECNUPAZ (pivekimab sunirine-pvzy).

📈 EPCORE FL-1 trial subgroup analysis shows numerically higher overall response rates for epcoritamab + lenalidomide + rituximab vs. standard care in high-risk follicular lymphoma patients.

⚖️ EPCORE DLBCL-1 trial results show statistically significant improvement in progression-free survival (30% vs 13% at 24 months) for epcoritamab monotherapy versus chemoimmunotherapy.

🦠 Higher rates of grade 3–4 infections (30% vs 12%) and COVID-19 (36% vs 11%) were reported in the epcoritamab arm of the DLBCL trial.

🧬 GAIA/CLL13 trial results predict efficacy of venetoclax-based therapies in previously untreated CLL patients lacking specific genetic mutations.

🔍 REVIVE study examines real-world management practices with venetoclax-based therapy for newly diagnosed AML patients unfit for intensive chemotherapy.

🧪 MONVISO study evaluates etentamig in relapsed/refractory multiple myeloma patients with prior BCMA-targeted therapy exposure.

🩺 Updated results from M24-209 show longer-term safety and efficacy of etentamig monotherapy in light chain amyloidosis.

🧬 CADENZA study presents post-hoc analysis of pivekimab sunirine-pvzy efficacy in blastic plasmacytoid dendritic cell neoplasm with skin involvement.

🤝 EPKINLY is co-developed by Genmab and AbbVie, with AbbVie responsible for global commercialization outside the U.S. and Japan.

⚠️ Important safety warnings include cytokine release syndrome, neurologic problems, infections, and low blood cell counts for epcoritamab.

🛡️ VENCLEXTA carries risks of tumor lysis syndrome, requiring specific hydration protocols and monitoring before and during treatment.

📊 Full abstracts and details on key presentations are available via the provided links in the press release.

Bullish Signals
  • 96.5% vs 84.8% ORR in low-risk FL-1 subgroup.
  • 30% 24-month PFS vs 13% with epcoritamab monotherapy.
  • No new safety signals observed in EPCORE FL-1.
  • Pipeline includes over 35 investigational medicines.
  • Etentamig shows promise in relapsed/refractory myeloma.
Risk Factors
  • DLBCL-1 trial showed no significant overall survival improvement for epcoritamab monotherapy.
  • Higher grade 3–4 infections (30% vs 12%) and COVID-19 (36% vs 11%) in epcoritamab arm.
  • Grade 5 adverse events occurred more frequently (17% vs 6%), largely due to severe COVID-19.
  • EPKINLY carries serious risks including CRS, neurologic issues, and potential hospitalization or death.
  • VENCLEXTA poses tumor lysis syndrome risk causing kidney failure requiring strict monitoring.
  • Etentamig and pivekimab sunirine-pvzy are investigational and not approved in the EU.
  • EPKINLY safety warnings include CRS, neurologic problems, and Day 15/22 Cycle 1 hospitalization needs.
Bullish Signals
  • EPCORE FL-1 trial subgroup analysis demonstrates numerically higher overall response rates (96.5% vs 84.8% in low-risk; 93.0% vs 72.6% in high-risk) for epcoritamab combination therapy compared to standard care.
  • EPCORE DLBCL-1 trial shows statistically significant improvement in progression-free survival with epcoritamab monotherapy (HR 0.74), achieving 30% 24-month PFS versus 13% for chemoimmunotherapy.
  • No new safety signals were observed across subgroups in the EPCORE FL-1 trial, indicating consistent tolerability of the epcoritamab combination therapy.
  • Venetoclax-based therapies show predicted efficacy in CLL patients based on genetic biomarkers, offering potential for personalized treatment approaches.
  • Real-world data from the REVIVE study provides insights into managing venetoclax-based therapy for AML patients who cannot tolerate intensive chemotherapy.
  • Etentamig shows promise in relapsed/refractory multiple myeloma even after prior exposure to BCMA-targeted therapies, addressing a critical unmet need.
  • Longer-term safety and efficacy data for etentamig in amyloidosis supports its potential as a durable treatment option for this rare disease.
  • AbbVie's robust pipeline includes more than 35 investigational medicines across blood cancers and solid tumors, demonstrating strong R&D commitment.
Risk Factors
  • EPCORE DLBCL-1 trial did not demonstrate a statistically significant improvement in overall survival for epcoritamab monotherapy versus chemoimmunotherapy.
  • Higher rates of grade 3–4 infections (30% vs 12%) and any-grade COVID-19 (36% vs 11%) were reported in the epcoritamab arm of the DLBCL trial.
  • Grade 5 treatment-emergent adverse events occurred more frequently in the epcoritamab arm (17% vs 6%), largely attributable to severe COVID-19 cases.
  • EPKINLY carries serious safety risks including cytokine release syndrome, neurologic problems, and infections that may lead to hospitalization or death.
  • VENCLEXTA poses a risk of tumor lysis syndrome, which can cause kidney failure and requires strict hydration and monitoring protocols.
  • Etentamig and pivekimab sunirine-pvzy are investigational therapies not approved in the EU, limiting immediate market access for these candidates.
  • Safety warnings for EPKINLY include risks of CRS and neurologic problems that may require step-up dosing schedules and hospitalization on Day 15 or 22 of Cycle 1.
Bullish +65

Why AbbVie Stock Price Is Capturing Attention: Insights for Investors

📈 Market cap exceeds $400 billion in healthcare sector.

💊 Humira sales hit $20B despite biosimilar competition.

🚀 Rinvoq sales surged 60% year-over-year recently.

💰 Dividend yield stands at 3.05% with growth.

🔬 R&D pipeline targets oncology and neurodegenerative diseases.

📈 AbbVie holds a market capitalization surpassing $400 billion, establishing it as a major player in the healthcare sector.

💊 The company's flagship product Humira generated over $20 billion in sales in 2022, though it faces biosimilar competition.

🚀 Newer immunology drugs Rinvoq and Skyrizi are gaining traction, with Rinvoq reporting a 60% increase in year-over-year sales.

💰 AbbVie offers an attractive dividend yield of 3.05% with a consistent track record of increasing payments to shareholders.

📊 Daily trading volume exceeds 6 million shares, indicating robust investor interest and liquidity.

🔬 The company is investing heavily in R&D for a pipeline targeting oncology, immunology, and neurodegenerative diseases.

🌍 AbbVie is actively pursuing regulatory approvals and partnerships in emerging markets like China, Brazil, and India.

📈 Analysts from Goldman Sachs and Morgan Stanley recently upgraded their ratings citing strong cash flow and pipeline diversity.

⚠️ Investors must monitor the impact of Humira's impending loss of exclusivity and biosimilar competition on revenue.

🛡️ AbbVie maintains a solid balance sheet with a low debt-to-equity ratio, providing flexibility for acquisitions and R&D.

Bullish Signals
  • Market cap exceeds $400 billion.
  • Dividend yield of 3.05% with consistent increases.
  • Rinvoq sales up 60% year-over-year.
  • Solid balance sheet with low debt-to-equity ratio.
  • Recent rating upgrades from Goldman Sachs and Morgan Stanley.
Risk Factors
  • Top drug Humira faces biosimilar competition after patent expiration.
  • Bristol Myers Squibb and others may pressure pricing and share.
  • Economic downturns could reduce healthcare spending and impact sales.
  • Humira exclusivity loss may cause volatile stock prices soon.
Bullish Signals
  • AbbVie has a market capitalization exceeding $400 billion, reflecting its status as a significant industry leader.
  • The company offers a compelling dividend yield of 3.05% with a history of consistent increases, appealing to income-focused investors.
  • Newer products like Rinvoq are showing strong momentum with a 60% year-over-year sales increase in the most recent quarter.
  • AbbVie maintains a solid balance sheet with a low debt-to-equity ratio, providing financial flexibility for future growth initiatives.
  • The company has received recent rating upgrades from major investment firms like Goldman Sachs and Morgan Stanley due to its strong cash flow.
  • AbbVie is successfully diversifying its portfolio beyond Humira to reduce reliance on a single product line.
  • The company is expanding its global footprint with active regulatory pursuits in emerging markets such as China, Brazil, and India.
Risk Factors
  • Humira, the company's top-selling drug, faces significant pressure from biosimilar competition following patent expiration.
  • Competition from established players like Bristol Myers Squibb, Pfizer, and Merck could lead to pricing pressures and market share challenges.
  • Global economic downturns or recessions could lead to reduced healthcare spending, potentially impacting sales for pharmaceutical companies.
  • The impending loss of exclusivity for Humira could lead to a more volatile stock price in the near term as revenue declines.
Bullish +75

5 Best Cheap Stocks to Buy for Beginners

🧬 AbbVie's AQUIPTA gains dual approval for acute and preventive migraine treatment in Europe.

🩸 VENCLYXTO expands label to treat previously untreated chronic lymphocytic leukemia patients.

📈 Insider Monkey strategy delivered +498.7% returns vs +195% benchmark from 2014 to 2026.

🧬 AbbVie Inc. (NYSE: ABBV) is highlighted as one of the best cheap stocks for beginners in this article.

💊 The European Commission approved AQUIPTA on June 2 for acute migraine treatment in adults with or without aura.

🛡️ AQUIPTA now holds dual approval as both an acute treatment and a once-daily preventive option for chronic or episodic migraine patients.

🔬 VENCLYXTO received expanded label authorization from the European Commission on May 29 for use with acalabrutinib or ibrutinib.

🩸 The expanded VENCLYXTO label covers treatment for adult patients with previously untreated chronic lymphocytic leukemia (CLL).

🏥 AbbVie is a research-based pharmaceutical company developing products for oncology, gastroenterology, rheumatology, dermatology, and virology.

📉 The article lists other cheap stocks like Sandisk, Moderna, Abivax, Navitas, PureCycle, and POET Technologies as top picks.

📈 Sandisk is noted to have soared to an all-time high with a 4,573% gain over one year.

🧬 Moderna climbed 7.5% ahead of key updates expected next week.

🚀 Abivax skyrocketed 24% following a steep fall in its stock price.

💻 Navitas hit an all-time high potentially due to Nvidia-related developments.

🔋 PureCycle added 6% on the success of its PureFive Living Hinge Cap.

🏭 POET Technologies soared 11%, mimicking the broader industry rally.

📊 Insider Monkey's quarterly strategy is reported to have returned +498.7%.

📈 The benchmark for comparison includes a 50% S&P 500 ETF and 50% Russell 2000 ETF with +195% returns.

📅 Returns data covers the period from May 2014 through February 18th, 2026.

🔒 A 30-day money-back guarantee is offered for subscribing to the service.

🚫 Readers are directed to visit a separate link for an extended list and methodology behind the picks.

Bullish Signals
  • AbbVie (NYSE: ABBV) got EU approval for AQUIPTA migraine treatment on June 2.
  • VENCLYXTO expanded label approved May 29 for CLL with acalabrutinib and ibrutinib.
  • EU Commission endorsed all-oral fixed-duration regimens as CLL care standards.
  • AbbVie sells products in oncology, gastroenterology, rheumatology, dermatology, and virology.
Bullish Signals
  • AbbVie Inc. (NYSE: ABBV) received European Commission approval on June 2 for AQUIPTA as a once-daily preventive treatment option for adults with chronic or episodic migraine who experience four or more migraine days per month.
  • The company secured authorization on May 29 for an expanded label for VENCLYXTO to include use in combination with acalabrutinib and ibrutinib to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL).
  • Management highlighted that the VENCLYXTO expansion follows the European Commission's inclusion of these combinations in the acalabrutinib and ibrutinib labels, reinforcing all-oral, fixed-duration combination regimens as current standards of care.
  • AbbVie continues to develop and sell products across multiple therapeutic areas including oncology, gastroenterology, rheumatology, dermatology, and virology.
Somewhat Bullish +50

AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine

🇪🇺 EU approves Aquipta for acute migraine treatment with or without aura.

💊 Approval based on ECLIPSE study showing pain freedom at two hours.

📈 Migraine portfolio revenues surged 26% to $2.88 billion in Q1 2026.

⚠️ Shares dropped 4.2% YTD despite strong sales growth from Ubrelvy and Qulipta.

🏥 Aquipta faces competition from established CGRP therapies like Emgality and Nurtec.

🇪🇺 The European Commission has approved AbbVie's Aquipta (atogepant) for the acute treatment of migraine in adults with or without aura.

💊 This marks the second EU indication for Aquipta, following its prior approval as a preventive CGRP receptor antagonist for patients with at least four migraine days per month.

📊 The approval was based on data from the pivotal phase III ECLIPSE study, which demonstrated statistically significant pain freedom compared to placebo at two hours post-dose.

⏱️ Clinical data showed that the treatment effect of Aquipta was sustained through 48 hours and remained consistent across multiple migraine attacks.

📈 AbbVie's neuroscience portfolio revenues increased 26% year-over-year to $2.88 billion in the first quarter of 2026, driven by strong performance from migraine medicines Ubrelvy and Qulipta.

💰 Ubrelvy sales rose 41% to $339 million in Q1 2026, while Qulipta generated $296 million in revenues, representing a 51% increase year-over-year.

🎯 Management estimates that the combined migraine portfolio of Ubrelvy and Qulipta/Aquipta represents a peak sales opportunity of over $3 billion.

⚠️ AbbVie's shares have lost 4.2% year-to-date, underperforming the industry which has seen an increase of 1.7%.

🏥 Aquipta faces competition from established CGRP-targeting therapies such as Teva's Ajovy, Eli Lilly's Emgality, and Pfizer's Nurtec ODT/Vydura.

🔄 Pfizer's Nurtec ODT/Vydura is approved for both acute and preventive use in certain markets, potentially increasing competitive pressure against Aquipta.

📉 AbbVie currently carries a Zacks Rank #3 (Hold) according to the analysis provided in the article.

🌍 The drug is marketed under the trade name Qulipta in the United States and several other countries across the world.

Bullish Signals
  • AbbVie got EU approval for Aquipta migraine treatment.
  • ECLIPSE study showed pain freedom at two hours.
  • Effect sustained through 48 hours across attacks.
  • Neuroscience revenues rose 26% to $2.88 billion.
  • Ubrelvy and Qulipta sales up 41% and 51%.
  • Combined peak sales opportunity exceeds $3 billion.
Risk Factors
  • AbbVie shares down 4.2% YTD vs industry gain of 1.7%.
  • Migraine market competition remains a concern for AbbVie.
  • Aquipta faces rivals Teva, Eli Lilly, and Pfizer.
  • Pfizer's Nurtec dual approval increases competitive pressure.
Bullish Signals
  • AbbVie received European Commission approval for Aquipta (atogepant) as an acute treatment for migraine, marking its second approved indication in the EU.
  • Pivotal phase III ECLIPSE study data demonstrated statistically significant pain freedom compared to placebo at two hours following the first migraine attack.
  • The treatment effect was sustained through 48 hours and remained clinically meaningful across multiple migraine attacks.
  • AbbVie's neuroscience portfolio revenues increased 26% year over year to $2.88 billion in the first quarter of 2026.
  • Migraine medicine Ubrelvy sales rose 41% year over year to $339 million, while Qulipta generated $296 million in revenues, up 51%.
  • Management indicates that Ubrelvy and Qulipta/Aquipta represent a combined $3 billion-plus peak sales opportunity.
Risk Factors
  • AbbVie's shares have lost 4.2% year-to-date, underperforming the industry which has increased by 1.7%.
  • Competition in the migraine market remains a concern for AbbVie's neuroscience portfolio.
  • Aquipta faces competition from established CGRP-targeting therapies such as Teva's Ajovy, Eli Lilly's Emgality, and Pfizer's Nurtec ODT/Vydura.
  • Pfizer's Nurtec is approved for both acute and preventive use in certain markets, potentially increasing competitive pressure on AbbVie's Aquipta.
Bullish +75

European Commission approves AbbVie’s Aquipta for the acute treatment of migraine in adults

🏛️ EU Commission approves Aquipta for acute migraine treatment in adults.

📉 Drug shows superiority over placebo with pain freedom at two hours.

💊 Administered as a single 60 mg oral dose taken as needed.

⚠️ Safety profile matches preventive use; common side effects are respiratory infections.

🏛️ The European Commission has approved AbbVie's Aquipta (atogepant) for the acute treatment of migraine in adults with or without aura.

💊 This approval marks the second indication for Aquipta in the EU, expanding its use from once-daily prevention to as-needed acute relief.

👥 The drug is indicated for both chronic and episodic migraine patients who experience four or more migraine days per month.

🗣️ Roopal Thakkar of AbbVie stated that this approval addresses unmet needs by offering a broad portfolio of acute and preventive treatments.

📉 Migraine affects approximately 14% of the global population, with a higher incidence in women and significant economic burdens.

💰 Recent analysis estimates migraine contributes between 1.2% to 2.0% of GDP in six European countries due to lost productivity.

🧠 Uwe Reuter from the European Headache Federation noted that Aquipta helps clinicians better address the socioeconomic burden of this invisible disease.

📊 The approval is supported by data from the phase 3 ECLIPSE study, which evaluated efficacy and safety versus placebo.

⚡ Aquipta demonstrated superiority to placebo in achieving pain freedom at two hours after treating the first migraine attack (p<0.0001).

🛡️ The drug showed statistical significance across secondary endpoints including reduced rescue medication use and sustained pain freedom up to 48 hours.

🩺 During the 16-week treatment period, Aquipta's safety profile was consistent with its approved preventive indication.

⚠️ The most common adverse events observed were nasopharyngitis and upper respiratory tract infection.

🌍 The ECLIPSE study enrolled 1,328 adults across 149 sites in Europe, the UK, Japan, China, South Korea, and Taiwan.

📅 Participants were randomized to treat four qualifying migraine attacks during a 16-week double-blind period followed by an open-label extension.

💊 Aquipta is administered as a single oral dose of atogepant (60 mg) taken as needed for acute treatment.

🔄 The drug functions as a calcitonin gene-related peptide (CGRP) receptor antagonist to block migraine pathways.

Bullish Signals
  • EC approves AbbVie Aquipta for acute migraine in EU.
  • ECLIPSE study showed Aquipta superior to placebo at 2 hours.
  • Aquipta demonstrated sustained pain freedom up to 48 hours.
  • AbbVie offers broad acute and preventive migraine treatments in Europe.
  • Pivotal phase 3 study enrolled 1,328 adults across 149 sites.
  • Aquipta safety profile consistent with approved preventive indication.
Risk Factors
  • Approval expands AbbVie portfolio without mentioning financial risks or market share threats.
  • Adverse events like nasopharyngitis may impact patient compliance if they persist.
Bullish Signals
  • The European Commission has approved AbbVie's Aquipta (atogepant) for the acute treatment of migraine in adults, marking a significant milestone and expanding its approved indications in the European Union.
  • Clinical data from the phase 3 ECLIPSE study demonstrated that Aquipta was superior to placebo in achieving pain freedom at two hours after treatment of the first migraine attack (p<0.0001).
  • The drug showed statistical significance versus placebo across key secondary endpoints, including sustained pain freedom up to 48 hours and reduced use of rescue medication within 24 hours.
  • AbbVie now offers a broad portfolio of acute and preventive treatments for chronic and episodic migraine in Europe, addressing unmet needs for patients with four or more migraine days per month.
  • The pivotal phase 3 study enrolled 1,328 adults across 149 sites in Europe, the United Kingdom, Japan, China, South Korea, and Taiwan, providing robust data on efficacy and safety.
  • Aquipta's safety profile during the 16-week treatment period was generally consistent with its approved preventive indication, with common adverse events limited to nasopharyngitis and upper respiratory tract infection.
Risk Factors
  • The approval expands AbbVie's portfolio but does not mention any specific financial risks or market share threats associated with this new indication.
  • Safety data indicates adverse events were consistent with the preventive indication, primarily nasopharyngitis and upper respiratory tract infections, which could impact patient compliance if these side effects persist in the acute setting.
Bullish +75

AbbVie Announces European Commission Approval of AQUIPTA&#174; (atogepant) for the Acute Treatment of Migraine in Adults

📅 EC approved AQUIPTA for acute migraine treatment in adults on June 2, 2026.

🔄 This is the second EU indication, adding PRN use to existing preventive approval.

📊 ECLIPSE trial proved superior pain freedom at two hours versus placebo (p<0.0001).

📅 AbbVie announced on June 2, 2026, that the European Commission has approved AQUIPTA® (atogepant) for the acute treatment of migraine in adults.

💊 The approval covers both adults with and without aura, allowing the medication to be taken as needed (PRN).

🔄 This marks the second indication for AQUIPTA in the EU, following its existing approval for once-daily preventive treatment in patients with at least four migraine days per month.

📊 Approval is based on data from the pivotal Phase 3 ECLIPSE trial, which demonstrated statistically significant pain freedom at two hours versus placebo during the first migraine attack.

⏱️ Clinical data showed sustained pain freedom lasting from 2 to 48 hours after treatment of a single migraine attack.

📈 The study met its primary endpoint with p<0.0001, showing superiority over placebo in achieving pain freedom at two hours post-treatment for the first attack.

🎯 Secondary endpoints included freedom from the most bothersome symptom, pain relief, reduced rescue medication use within 24 hours, and consistent effects across multiple attacks.

👥 The ECLIPSE study enrolled 1,328 adults aged 18 to 75 years across 149 sites in Europe, the UK, Japan, China, South Korea, and Taiwan.

⚠️ During the 16-week double-blind period, the most common adverse events were nasopharyngitis and upper respiratory tract infection, consistent with the preventive treatment profile.

🤢 Nausea was reported as the most common adverse drug reaction during acute treatment studies (9%), followed by constipation (8%) and fatigue/somnolence (5%).

⚠️ AQUIPTA is contraindicated in patients with hypersensitivity to atogepant or any excipients and is not recommended for patients with severe hepatic impairment.

🤰 The drug is not recommended during pregnancy or for women of childbearing potential not using contraception, though minimal transfer into breast milk was observed.

🚗 Patients should exercise caution when driving or using machinery as the drug may cause somnolence in some individuals.

🌍 Migraine affects roughly 14% of the global population and is a leading cause of years lived with disability, particularly among women aged 25 to 55.

💰 In six European countries, migraine contributes an estimated economic burden of €35 billion to €557 billion in lost productivity from paid and unpaid work.

🏢 AbbVie's executive vice president Roopal Thakkar stated that this approval addresses unmet needs for acute treatment options in Europe.

👨‍⚕️ Uwe Reuter, president of the European Headache Federation, noted that effective treatment can help clinicians better address the socioeconomic burden of migraine.

🌐 AQUIPTA is marketed as QULIPTA® in the U.S., Canada, Israel, and Puerto Rico, while retaining the name AQUIPTA in the EU.

🔬 The ECLIPSE trial was a 24-week, multicenter, randomized, double-blind, placebo-controlled multiple-attack study with an open-label extension.

📄 More information on the ECLIPSE trial can be found at www.clinicaltrials.gov under identifier NCT06241313.

⚖️ AbbVie cautioned that forward-looking statements in the release are subject to risks including competition, intellectual property challenges, and global macroeconomic factors.

Bullish Signals
  • AbbVie received EU approval for AQUIPTA as second migraine indication.
  • ECLIPSE trial showed significant pain freedom at two hours vs placebo.
  • Sustained pain freedom from 2 to 48 hours provided lasting relief.
  • Drug demonstrated consistent effect across multiple acute migraine attacks.
  • AQUIPTA met primary endpoint of superior efficacy versus placebo.
  • Study showed reduced rescue medication use within 24 hours.
  • 16-week safety profile consistent with approved preventive indication.
Risk Factors
  • EU-only approval limits US (QULIPTA) and other market access.
  • Nausea affects 9% of patients; 0.4% discontinuation rate hinders uptake.
  • Contraindicated for hypersensitivity or severe hepatic impairment restricts use.
  • Not recommended during pregnancy or without contraception limits access.
  • Somnolence may cause drowsiness, requiring caution before driving.
Bullish Signals
  • AbbVie received European Commission approval for AQUIPTA® (atogepant) as the second indication in the EU, expanding its migraine therapy portfolio to include both acute treatment and once-daily prophylaxis.
  • The pivotal Phase 3 ECLIPSE trial demonstrated that AQUIPTA achieved statistically significant pain freedom at two hours versus placebo during the first migraine attack (p<0.0001).
  • Clinical data showed sustained pain freedom from 2 to 48 hours, providing fast and lasting relief for patients with acute migraine attacks.
  • The drug demonstrated a clinically meaningful and consistent effect across multiple migraine attacks, addressing unmet needs in the European market.
  • AQUIPTA met its primary endpoint of superior efficacy versus placebo in achieving pain freedom at two hours after treatment of the first migraine attack.
  • The study showed statistical significance versus placebo for secondary endpoints including reduced use of rescue medication within 24 hours and absence of the most bothersome symptom.
  • Safety data from the 16-week treatment period indicated that AQUIPTA's safety profile was consistent with its approved preventive indication, with common adverse events limited to nasopharyngitis and upper respiratory tract infection.
Risk Factors
  • The approval is limited to the European Union, leaving other markets such as the US (where it is marketed as QULIPTA) and others potentially subject to different regulatory timelines or outcomes.
  • Nausea remains a significant adverse event, occurring in 9% of patients overall and being the most common reason for discontinuation (0.4%), which could impact patient adherence and real-world uptake.
  • The drug is contraindicated in patients with hypersensitivity to atogepant or excipients and not recommended for those with severe hepatic impairment, limiting its use in specific patient populations.
  • AQUIPTA is not recommended during pregnancy and for women of childbearing potential not using contraception, which may restrict access for a segment of the migraine population.
  • While somnolence has negligible influence on driving ability overall, it may still cause drowsiness in some patients, requiring caution before operating machinery or driving.
  • The forward-looking statements explicitly warn that actual results may differ materially due to risks including challenges to intellectual property and competition from other products.
Somewhat Bullish +50

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

📈 AbbVie revenue grew 8.6% to $61.2B while Pfizer declined 1.6% to $62.6B.

💰 Pfizer posted higher net income ($7.8B) and better margins than AbbVie.

⚠️ AbbVie carries high debt but faces product concentration risks from Humira loss.

🛡️ Pfizer maintains a healthier balance sheet with lower leverage and current ratios.

🎯 Analysts favor Pfizer's valuation, while conservative investors prefer AbbVie's growth outlook.

📊 AbbVie generated approximately $61.2 billion in revenue for FY 2025, representing an 8.6% increase from the prior year.

💰 The company reported net income of about $4.2 billion with a net margin of roughly 6.9%.

⚠️ AbbVie's balance sheet shows a debt-to-equity ratio of -21.1x, indicating total liabilities exceed shareholder equity.

📉 Despite high leverage, the firm generated nearly $17.8 billion in free cash flow during FY 2025.

🏥 Pfizer operates as a diversified global leader with manufacturing sites serving patients in roughly 200 countries.

💵 Pfizer reported revenue of nearly $62.6 billion for FY 2025, a slight decline of 1.6% from the previous year.

📈 The company achieved net income close to $7.8 billion with a net margin of approximately 12.4%.

🛡️ Pfizer's balance sheet displays a debt-to-equity ratio of 0.8x and a current ratio of roughly 1.2x.

🏭 AbbVie relies heavily on three major wholesale distributors for nearly all its pharmaceutical sales in the United States.

💊 Two major products currently account for nearly 42% of AbbVie's total revenue, creating concentration risk.

⚠️ Pfizer faces significant patent expirations between 2026 and 2030 that could lead to substantial revenue reductions.

📉 Pfizer's high dividend yield reflects investor concerns about its future growth and ability to sustain payouts.

🧬 AbbVie is navigating the loss of exclusivity on Humira while growing revenue with Skyrizi and Rinvoq.

🔍 Analysts suggest Pfizer appears more affordable based on Forward P/E and P/S ratios compared to AbbVie.

🎯 A conservative investor perspective favors AbbVie for its stronger growth outlook and predictable business performance.

📉 The Motley Fool Stock Advisor team recently identified 10 best stocks to buy, but AbbVie was not included in the list.

Bullish Signals
  • Strong immunology and oncology pipeline drives $61.2B annual revenue.
  • FY 2025 revenue rose 8.6% to $61.2B.
  • FY 2025 net income reached $4.2B with 6.9% margin.
  • Generated $17.8B free cash flow despite high debt.
  • Skyrizi and Rinvoq offset Humira revenue decline.
  • Consistent dividends provide reliable investor income.
  • Stronger growth outlook than competitors.
Risk Factors
  • AbbVie debt-to-equity is -21.1x with current ratio at 0.7x.
  • AbbVie revenue relies on two products accounting for nearly 42%.
  • Biosimilar competition and IRA pricing pressures threaten AbbVie margins.
  • Manufacturing complexity exposes AbbVie to supply chain disruptions.
  • Pfizer faces patent expirations between 2026 and 2030.
  • Generic competition and rivals like Merck challenge Pfizer.
  • R&D costs and cybersecurity risks burden Pfizer operations.
  • Pfizer's high dividend yield may signal growth concerns.
  • AbbVie excluded from Motley Fool Stock Advisor top 10 list.
Bullish Signals
  • AbbVie leverages a strong pipeline in immunology and oncology to drive nearly $61.2 billion in annual revenue.
  • In FY 2025, AbbVie revenue reached approximately $61.2 billion, representing an increase of nearly 8.6% from the prior year.
  • The company reported net income of about $4.2 billion for FY 2025, resulting in a net margin of roughly 6.9% as it integrated newer products.
  • Despite a debt-to-equity ratio exceeding equity, AbbVie generated free cash flow of nearly $17.8 billion in FY 2025.
  • AbbVie has successfully offset the decline in Humira revenue with growth from Skyrizi and Rinvoq, demonstrating its ability to develop new medications.
  • The company maintains consistent dividend payments to shareholders, providing reliable income for investors.
  • AbbVie is characterized as having a stronger growth outlook and more predictable business performance compared to competitors.
Risk Factors
  • AbbVie's debt-to-equity ratio is -21.1x as of December 2025, indicating total liabilities significantly exceed shareholder equity.
  • The company's current ratio stands at approximately 0.7x, suggesting potential difficulty in meeting short-term obligations with short-term assets.
  • AbbVie faces significant revenue concentration risk, with two major products accounting for nearly 42% of its 2025 revenue.
  • The company is vulnerable to intensifying competition from biosimilars and pricing pressures stemming from the Inflation Reduction Act.
  • Complex biologics manufacturing exposes AbbVie to supply chain disruptions and single-source supplier issues.
  • Pfizer expects a significant revenue reduction as several key patents expire between 2026 and 2030.
  • Pfizer faces stiff competition from generic manufacturers and other pharmaceutical giants like Merck and Johnson & Johnson.
  • Pfizer must manage cybersecurity risks and the high costs associated with potentially unsuccessful research and development projects.
  • Pfizer's higher dividend yield may reflect investor concerns about the company's future growth and ability to sustain dividend payments.
  • AbbVie was not included in The Motley Fool Stock Advisor analyst team's list of 10 best stocks for investors to buy now.
Slightly Bullish +25

VIDEO: Triple therapy regimens being explored for acute myeloid leukemia

📉 P53-mutated AML patients achieve similar outcomes with hypomethylators as high-intensity chemotherapy.

💊 Current standards include high-intensity induction or venetoclax combined with hypomethylating agents.

💉 Clinicians can now empirically use triple therapy regimens outside of clinical trials.

📄 This article features a video transcript discussing triple therapy regimens for acute myeloid leukemia (AML).

🧬 A 2016 New England Journal of Medicine paper introduced using genomic information, specifically TP53 mutations, to decide on therapy.

💊 Before the 2016 study, fit patients received "7 + 3" chemotherapy while unfit patients received hypomethylating agents.

📉 The study showed that patients with P53 mutations achieved similar results with hypomethylators as with high-intensity "7 + 3" therapy.

🛑 Consequently, clinicians stopped giving high-intensity "7 + 3" to fit patients with P53 mutations or 17p deletions to avoid side effects.

⚖️ Current frontline standards of care for AML include either high-intensity induction or hypomethylating agents combined with venetoclax (Venclexta).

🔬 Clinical trials are now comparing triple therapy regimens against standard "7 + 3" plus an inhibitor to determine necessary chemo intensity.

💉 Triple therapy combinations may include azacitidine or decitabine, venetoclax, and a targeted agent like an IDH1/2, NPM1, or FLT3 inhibitor.

🏥 Since the drugs are commercially available, clinicians can already implement these triple therapy regimens empirically outside of trials.

🔄 The empirical approach involves giving two drugs first and adding a third agent if the patient's response is suboptimal.

🎯 These concepts aim to explore how much chemotherapy intensity is necessary for patients with targetable mutations.

👨‍⚕️ Noah Merin, MD, PhD, an assistant professor at Cedars-Sinai Medical Center, is the speaker featured in this report.

Bullish Signals
  • Venetoclax is now part of frontline AML standards.
  • Clinicians can use triple therapy regimens empirically.
  • TP53 mutations enable lower intensity treatments avoiding side effects.
  • IDH1/2 and FLT3 inhibitors target specific AML mutations.
  • Minimal residual disease tests improve patient care matching.
Risk Factors
  • No cure exists for acute myeloid leukemia (AML).
  • Current standards insufficient for patients with targetable mutations.
  • Two-drug regimens often fail to achieve optimal outcomes.
  • Treatment landscape uncertain during transition to triple therapy.
  • Incomplete data on chemo intensity for mutation-positive patients.
Bullish Signals
  • Venetoclax (Venclexta), a commercially available drug from AbbVie and Genentech, is now part of competing standards of care for frontline AML treatment.
  • Clinicians can already implement triple therapy regimens empirically using commercially available drugs ahead of clinical trials, allowing for flexible patient-specific treatment approaches.
  • The ability to use genomic information like TP53 mutations to decide on therapy has improved patient outcomes by enabling lower intensity treatments that avoid severe side effects.
  • Emerging targeted agents such as IDH1/2 inhibitors and FLT3 inhibitors offer new options to address specific mutations in AML patients.
  • Minimal residual disease tests are advancing to better match patients with appropriate care, potentially improving treatment efficacy.
Risk Factors
  • The article highlights that the lack of a cure remains the biggest challenge in acute myeloid leukemia (AML).
  • Clinicians are currently exploring triple therapy regimens because existing standards of care may not be sufficient for all patients with targetable mutations.
  • Some patients may require empiric addition of third agents after suboptimal response to two-drug regimens, indicating current therapies may not achieve optimal outcomes initially.
  • The field is still transitioning from high-intensity induction or hypomethylator with venetoclax to new triple therapy combinations, suggesting uncertainty in the optimal treatment landscape.
  • Clinical trials are needed to determine how much chemo intensity is necessary for patients with targetable mutations, implying current data on efficacy is incomplete.
  • Future therapies targeting more common mutations in AML are still hoped for, indicating current options may not cover all patient populations effectively.
Somewhat Bullish +50

AbbVie Advances New Autoimmune Drug ABBV-519 Into First-in-Human Trial, Signaling Next Wave in Immunology

🧬 AbbVie advances autoimmune drug ABBV-519 into first-in-human Phase 1 trial.

💉 Study tests safety via IV or subcutaneous injection in SLE and RA patients.

🚀 Progress aims to build next-gen immunology assets beyond current blockbuster drugs.

🧬 AbbVie has advanced its experimental autoimmune drug ABBV-519 into a first-in-human Phase 1 clinical trial.

📋 The study is an open-label, non-randomized, single ascending dose trial evaluating pharmacokinetics and safety in adults with Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA).

💉 ABBV-519 can be administered via intravenous infusion or subcutaneous injection to determine safe exposure levels for future larger trials.

📅 The trial was formally submitted on May 20, 2026, with a recruiting update confirmed on May 28, 2026.

🔬 This early-stage study focuses on basic science safety and drug behavior rather than demonstrating clear clinical benefit at this stage.

🚀 Progress on ABBV-519 represents AbbVie's effort to build the next wave of immunology assets beyond current blockbusters like Humira and Skyrizi.

⚖️ Successful development could help defend AbbVie's market share against rivals such as Eli Lilly and Johnson & Johnson in the autoimmunity space.

📈 While Phase 1 data rarely moves a large-cap stock like ABBV significantly, continued pipeline progress can support long-term sentiment and valuation multiples.

🌐 Further details regarding the trial are available on the ClinicalTrials.gov portal.

Bullish Signals
  • AbbVie advances autoimmune drug ABBV-519 into first-in-human trial.
  • Phase 1 study recruits patients for SLE or RA.
  • ABBV-519 builds new immunology assets beyond Humira and Skyrizi.
  • Trial submission on May 20, 2026 marks formal launch.
  • May 28, 2026 update confirms active patient recruitment.
  • Clean safety could support AbbVie's long-term growth story.
  • Drug offers flexible IV or subcutaneous administration options.
  • Interventional non-randomized design allows efficient dose-finding.
  • Pipeline progress supports sentiment and valuation multiples over time.
Risk Factors
  • Phase 1 is non-randomized open-label focusing only on basic science safety.
  • ABBV Phase 1 data rarely moves large cap stock lasting valuation.
  • Trial ongoing with definitive results unavailable until ClinicalTrials portal update.
  • Long-term growth depends on ABBV-519 showing clean safety and activity.
Bullish Signals
  • AbbVie advances new autoimmune drug ABBV-519 into first-in-human trial, signaling next wave in immunology growth.
  • The Phase 1 study is actively recruiting patients for SLE or RA, confirming active site startup and early screening progress.
  • ABBV-519 aims to build a new pipeline of immunology assets beyond current blockbusters like Humira and Skyrizi.
  • Successful development could support AbbVie's long-term growth story and help defend market share against rivals such as Eli Lilly and Johnson & Johnson.
  • The trial submission on May 20, 2026 marks the formal launch of this first-in-human program.
  • The latest update on May 28, 2026 confirms the trial is recruiting, which signals active site startup and early screening of patients.
  • If ABBV-519 later shows clean safety and useful activity, it could support AbbVie's long term growth story and help defend share against rivals such as Eli Lilly and Johnson & Johnson in autoimmunity.
  • The study was first submitted on May 20, 2026, marking the formal launch of this first in human program.
  • The latest update on May 28, 2026 confirms the trial is recruiting, which signals active site start up and early screening of patients.
  • Investors should see this as an early but important step in AbbVie's effort to build its next wave of immunology assets beyond current blockbusters like Humira and Skyrizi.
  • The Phase 1 study aims to understand safety, how the drug moves through the body, and early signs of effect, which could open a new growth area in autoimmune care.
  • ABBV-519 is an experimental drug given either by intravenous infusion or subcutaneous injection, offering flexible administration options for patients.
  • The trial is interventional and non randomized, with participants assigned to dose groups in sequence rather than by chance, allowing for efficient dose-finding.
  • The study remains ongoing and updated, with further details available on the ClinicalTrials portal.
  • While Phase 1 data alone rarely moves a large cap stock like ABBV in a lasting way, continued pipeline progress can support sentiment and valuation multiples over time.
  • To learn more about ABBV's potential, visit the Abbvie drug pipeline page.
Risk Factors
  • The Phase 1 study is non-randomized and open-label, meaning it focuses on basic science safety rather than demonstrating clear clinical benefit at this stage.
  • Phase 1 data alone rarely moves a large cap stock like ABBV in a lasting way, limiting the immediate impact of this announcement on valuation.
  • The trial is ongoing with further details available only on the ClinicalTrials portal, indicating that definitive results are not yet available to investors.
  • AbbVie's long-term growth story depends on ABBV-519 later showing clean safety and useful activity, introducing significant uncertainty regarding future pipeline success.